|
Published by: Datamonitor
Published: Nov. 5, 2001 - 153 Pages
Table of Contents
DATAMONITOR HEALTHCARE
CONTACT DETAILS
EXECUTIVE SUMMARY
Scope
Datamonitor insight into antidepressant treatment strategies
Key metrics
TABLE OF CONTENTS
INTRODUCTION
Psychiatrist Sample
Overview of analyzed drugs
Paxil
Prozac
Zoloft
Effexor
Wellbutrin
Celexa
Serzone
Luvox
Remeron
Edronax
Ixel
Tricyclic antidepressants
Monoamine oxidase inhibitors
BuSpar
Benzodiazepines
St John's Wort
Overview of report
Chapter Three: Treatment of Mood Disorders
Chapter Four: Current Therapies
Chapter Five: Drug Switching
Chapter Six: Unmet Needs
Chapter Seven: The Future Decoded
TREATMENT OF MOOD DISORDERS
Impact of anxiety indications on antidepressant use
Introduction
First-line anxiety treatment
Comorbidities
Level of mood disorder comorbidity
Disorders comorbid with major depression
Approach to treatment of comorbidites
Conclusion
General influencing factors over treatment management
Drug efficacy
Drug side effect profile
Drug tolerability/safety
Drug onset of action
Clinical trial data
Patient request
Cost of drug
Influence of drug indications in other countries
The level of impact
The influence of individual markets
Influence of publicized clinical trial results
CURRENT THERAPIES
Individual influencing factors upon drug choice
Drug characteristics
The treatment of acute depression
The treatment of maintenance depression
The treatment of acute anxiety
The treatment of maintenance anxiety
Drug tolerability
Patient compliance
Overall side effect profile
Sexual dysfunction side effect
Treating refractory depression
Treating refractory anxiety
Drug cost
Dosage regimen
Drug formulation
Use in combination therapy
Off-label prescribing
Overall rating
Physician drug perceptions
Citalopram
Paroxetine
Sertraline
Mirtazapine
Fluoxetine
Venlafaxine
Other leading antidepressants
Antidepressant prescribing
DRUG SWITCHING
A successful patient
Definition of a successful treatment
Time to therapy failure
First line treatment
Further lines of therapy
The switching choice
Influencing factors upon further drug choice
Reasons for switching to a different class
UNMET NEEDS
Unmet needs ranking
Physicians' viewpoint: what single improvement is needed?
Unmet need of marketed antidepressants
Fluoxetine
Paroxetine
Sertraline
Venlafaxine
Citalopram
Mirtazapine
Nefazodone
Fluvoxamine
Reboxetine
Conclusion
THE FUTURE DECODED
New antidepressant medications
Physicians' viewpoint: necessary drug chracteristics for commercial success
Factors needed to become the gold standard
Physician knowledge of pipeline drugs
Hypothetical scenarios
Antidepressant without anxiolytic effect
Antidepressant with lower efficacy but faster onset
Antidepressant with lower efficacy but no sexual dysfunction side effect
Antidepressant with lower efficacy but no weight gain side effect
APPENDIX
Datamonitor's Central Nervous System Business Unit
Contributing experts
Table of tables
Bibliography
Websites
Physician research questionnaire
AbstractThe treatment of mood disorders altered rapidly over the 1990s. The uptake of second-generation antidepressants fuelled massive market growth that was driven by pharmaceutical manufacturers positioning their products in the anxiety disorders market, as well as depression. Consequently, the second-generation antidepressant are now recognized as being the gold standard treatment in mood and physicians now offered multiple pharmacological options when treating their patients. Strategic Perspectives 2001: Antidepressant Treatment Strategies - Efficacy Drives Psychiatrist Drug Choice investigates how psychiatrists make this drug choice, which factors influence their decision and whether depression or anxiety takes priority. Each leading antidepressant is subjected to in-depth physician analysis, with further investigations into unmet needs, drug switching, plus physician responses to antidepressant clinical trial design and a number of hypothetical drug launch scenarios
Get Full Details About This Report >>
|
